Navigation Links
Bunge Reports Fourth Quarter Net Income of $245 Million
Date:2/7/2008

reholders $230 $260 (12)% $738 $517 43%

Earnings per common

share - diluted

(Note 1): $1.82 $2.12 (14)% $5.95 $4.28 39%

Weighted-average

common shares

outstanding

-diluted

(Note 1) 134,501,104 124,409,362 130,753,807 120,849,357

Note 1: The dilutive effect of the of 11,661,359 and 8,536,729 weighted

average common shares, which would be issuable upon conversion of

Bunge's convertible preference shares, is included in the

earnings per common share - diluted calculation for the quarter

and year ended December 31, 2007, respectively, because the

effect of the conversion would have been dilutive.

CONSOLIDATED SEGMENT INFORMATION

(In millions, except volumes and percentages)

(Unaudited) (Note 1 and 2)

Set forth below is a summary of certain items in our consolidated

statements of income and volumes by reportable segment.

Quarter Ended Year Ended

December 31, Percent December 31, Percent

2007 2006 Change 2007 2006 Change

Volumes (in thousands

of metric tons):

Agribusiness 28,104 24,645 14% 114,365 99,801 15%

Fertilizer 3,548 3,921 (10)% 13,077 11,578 13%

Edible oil products 1,461 1,266 15% 5,530 4,777 16%

Milling products 973 933 4% 3,983 3,895 2%

Total 34,086 30,765 11% 136,955 120,051 14%

Net sales:

Agribusiness $10,481 $5,471 92% $33,877 $18,909 79%

Fertilizer 1,280 918 39% 3,944 2,602 52%

Edible oil products 1,840 1,043 76% 5,622 3,798 48%

Milling prod
'/>"/>

SOURCE Bunge Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. Digirad Corporation Reports Financial Results for 2007 Fourth Quarter and Twelve Months
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. Senesco Technologies Reports on Results of Preclinical Multiple Myeloma Studies
4. Recent Research Reports and Near-Term Corporate Events
5. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
6. Thermo Fisher Scientific Reports Record 2007 Fourth Quarter Revenues and Operating Performance; Provides Guidance for 2008
7. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
8. Rochester Medical Reports 31% Increase in Branded Sales Resulting in 9% Overall Sales Growth for the First Quarter
9. Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
10. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
11. Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 2Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 3Publication in Neuropsychopharmacology Confirms CeNeRx's Novel RIMA Antidepressant TriRima(TM) Selectively and Reversibly Inhibits MAO-A 4WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening 2Alberta companies delivering new products to the health & medical marketplace 2